| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, MET Amplification
Test Code91283
CPT Codes
88271 (x2), 88275
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue
Minimum Volume
Tumor biopsy: 5x5 mm
Other Acceptable Specimens
5x5 mm tumor tissue collected in culture transport medium • 4-5 microns sections on charged slides (x5)
Instructions
For MET determination in solid tumors, only biopsies with histologically proven tumor involvement should be tested. Samples that can be tested include tumor biopsy in tissue culture media, formalin fixed paraffin-embedded block, or a minimum of 4 charged/+ slides from formalin fixed paraffin embedded tissue. Specimen must be fixed in 10% neutral buffered formalin. Fixation between 6 and 48 hours is recommended. Pathology report must accompany paraffin block or slides.
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 7 days a week.
Clinical Significance
The proto-oncogene MET (c-MET) product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. Overexpression of MET has been observed in variety of neoplasms such as kidney, lung, head and neck, ovary, breast, thyroid, brain, stomach, pancreas and colon. MET gene amplification, detected by FISH, has been associated with an unfavorable prognosis in non-small cell lung cancer (NSCLC) and resistance to EGFR inhibitors.
